Table 6.
TEAEs by preferred term in ≥5% of evaluable patients with C3G and in the overall study population
| Preferred term | C3G (n = 8) | Overall (N = 21) |
|---|---|---|
| Any TEAE, n (%) | 8 (100) | 19 (90.5) |
| Upper respiratory tract infection | 2 (25.0) | 5 (23.8) |
| Nasopharyngitis | 1 (12.5) | 3 (14.3) |
| Sinusitis | 3 (37.5) | 3 (14.3) |
| Pneumonia | 1 (12.5) | 2 (9.5) |
| Injection site erythema | 1 (12.5) | 4 (19.0) |
| Injection site pruritus | 2 (25.0) | 3 (14.3) |
| Fatigue | 2 (25.0) | 2 (9.5) |
| Injection site discomfort | 0 | 2 (9.5) |
| Injection site induration | 2 (25.0) | 2 (9.5) |
| Injection site rash | 2 (25.0) | 2 (9.5) |
| Pyrexia | 2 (25.0) | 2 (9.5) |
| Nausea | 3 (37.5) | 4 (19.0) |
| Diarrhea | 2 (25.0) | 3 (14.3) |
| Vomiting | 3 (37.5) | 3 (14.3) |
| Headache | 3 (37.5) | 4 (19.0) |
| Dizziness | 1 (12.5) | 3 (14.3) |
| Migraine | 2 (25.0) | 3 (14.3) |
| Dyspnea | 2 (25.0) | 2 (9.5) |
| Oropharyngeal pain | 1 (12.5) | 2 (9.5) |
| Anemia of chronic disease | 1 (12.5) | 2 (9.5) |
| Acute kidney injury | 0 | 3 (14.3) |
| Depression | 1 (12.5) | 2 (9.5) |
C3G, C3 glomerulopathy; TEAE, treatment-emergent adverse event.